Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Key NSCLC updates

Jarushka Naidoo • 4 Nov 2020
Lung Cancer Non-Small Cell Lung Cancer Capmatinib Crizotinib Ipilimumab Lorlatinib Nivolumab Osimertinib Tepotinib Trastuzumab deruxtecan
ADAURA CheckMate 9LA CROWN

Jarushka Naidoo, MBBCh, Beaumont Hospital, Dublin, Ireland, outlines key non-small cell lung cancer (NSCLC) updates from the virtual Gathering Around Cancer 2020 Irish meeting, including novel targeted therapies designed for EGFR, ALK, ROS1, MET and KRAS mutated patients, as well as advances in immunotherapy such as combination ipilimumab and nivolumab which may show benefit in NSCLC patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology)

More from Jarushka Naidoo

1:11
Unanswered questions regarding the use of IO in NSCLC
Jarushka Naidoo • 5 Jun 2022
1:28
Highlights in NSCLC from ASCO 2022
Jarushka Naidoo • 5 Jun 2022
0:48
Chemotherapy-free immunotherapy-based treatment approaches for NSCLC
Jarushka Naidoo • 5 Jun 2022
1:44
Post-hoc subgroup analysis from PACIFIC: durvalumab after CRT in unresectable stage III EGFRm NSCLC
Jarushka Naidoo • 5 Jun 2022

Related Videos

1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
0:57
STK-012-101: STK-012 in advanced solid tumors
Alexander Spira • 15 Mar 2024
3:34
FLAURA2: EGFRm dynamics in NSCLC treated with osimertinib
Pasi Jänne • 8 Apr 2024
0:54
FURVENT: furmonertinib in EGFR exon 20 mutant NSCLC
Alexander Spira • 15 Mar 2024
The content of VJOncology is intended for healthcare professionals